|
| Status |
Public on Jan 13, 2021 |
| Title |
Serine biosynthesis is a metabolic vulnerability in FLT3-ITD-driven acute myeloid leukaemia [MV411_OCI-AML3_DMSO_AC220_24hr] |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
We performed 3'-RNA-Sequencing on RNA isolated from human MV4-11 and OCI-AML3 cells which had been treated with DMSO or the FLT3 inhibitor Quizartinib (AC220) to perform differential gene expression analysis.
|
| |
|
| Overall design |
Cells were treated with 5 nM Quizartinib (AC220) for 24 hours in vitro. Total RNA was isolated from cells and 3'-RNA libraries were prepared for next-generation sequencing.
|
| |
|
| Contributor(s) |
Bjelosevic S, Gruber E, Vervoort SJ, Brown KK, Johnstone RW |
| Citation(s) |
33436370 |
| |
| Submission date |
Dec 28, 2020 |
| Last update date |
Apr 14, 2021 |
| Contact name |
Stefan Bjelosevic |
| E-mail(s) |
stefan.bjelosevic@petermac.org
|
| Organization name |
Peter MacCallum Cancer Centre
|
| Department |
Translational Haematology Program
|
| Street address |
305 Grattan Street
|
| City |
Melbourne |
| State/province |
VIC |
| ZIP/Postal code |
3000 |
| Country |
Australia |
| |
|
| Platforms (1) |
| GPL18573 |
Illumina NextSeq 500 (Homo sapiens) |
|
| Samples (12)
|
|
| This SubSeries is part of SuperSeries: |
| GSE163932 |
Serine biosynthesis is a metabolic vulnerability in FLT3-ITD-driven acute myeloid leukaemia |
|
| Relations |
| BioProject |
PRJNA688229 |
| SRA |
SRP299462 |
Less...
More...